Aller au contenu
Trouver un autre spécialiste

Artuela Cacani Çaku

Professeure, Faculté de médecine et des sciences de la santé
FMSS Département de biochimie et de génomique fonctionnelle

Présentation

Diplômes

  • (2015-2016). Fellowship. Molecular Biology. McMaster University Faculty of Health Sciences. Hamilton, ON, Canada.
  • (2009-2015). MD, FRCP(C). Medicine. Université de Sherbrooke. Sherbrooke, QC, Canada.
  • (2013-2015). Clinical Investigator. Clinical Sciences. Université de Sherbrooke. Sherbrooke, Quebec, Canada.
  • (2013-2015). M.Sc. Clinical Sciences. Université de Sherbrooke. Sherbrooke, QC, Canada.

Expériences académiques

  • Profesor (Biochemistry). (2016-). Université de Sherbrooke. Sherbrooke, QC, Canada.
  • Dr (Medical Biology). (2016-). Centre Hospitalier Universitaire de Sherbrooke. Sherbrooke, QC, Canada.

Publications

Articles

  • Jean Dubé, Rosalie Plantefève, Maude Bonin, Luc Galarneau, Jean-Denis Rousseau, François Corbin, Charles Ménard, Artuela Çaku. (2026). Thresholds adjustments and impact on clinical performance of three FIT assays in a colorectal cancer screening program. Clinical Chemistry and Laboratory Medicine (CCLM). DOI
  • Laroui A, Rojas D, Bouhour S, Proteau-Lemieux M, Galarneau L, Benachenhou S, Abolghasemi A, Plantefeve R, Mallet PL, Corbin F, Lepage JF, Çaku A. (2025). Associations between plasma 24(S)-hydroxycholesterol and neuropsychological profile in fragile X syndrome. Journal of lipid research. DOI
  • Morin-Parent F, Champigny C, Côté S, Mohamad T, Hasani SA, Çaku A, Corbin F, Lepage JF. (2024). Neurophysiological effects of a combined treatment of lovastatin and minocycline in patients with fragile X syndrome: Ancillary results of the LOVAMIX randomized clinical trial. Autism research : official journal of the International Society for Autism Research. DOI
  • Dionne O, Abolghasemi A, Corbin F, Çaku A. (2024). Implication of the endocannabidiome and metabolic pathways in fragile X syndrome pathophysiology. Psychiatry research. DOI
  • Bouhour S, Plantefève R, Gillet V, Abolghasemi A, Bouchouirab FZ, Baccarelli AA, Takser L, Çaku A. (2024). Establishing non-fasting reference values for plasma lipids levels based on age, sex, and puberty stage in a French-Canadian pediatric population. Lipids in health and disease. DOI
  • Rojas D, Benachenhou S, Laroui A, Aden AA, Abolghasemi A, Galarneau L, Irakoze TJ, Plantefeve R, Bouhour S, Toupin A, Corbin F, Fink G, Mallet PL, Çaku A. (2023). Development and validation of a liquid chromatography-tandem mass spectrometry assay to quantify plasma 24(S)-hydroxycholesterol and 27-hydroxycholesterol: A new approach integrating the concept of ion ratio. The Journal of steroid biochemistry and molecular biology. DOI
  • Raal F, Fourie N, Scott R, Blom D, De Vries Basson M, Kayikcioglu M, Caldwell K, Kallend D, Stein E, LIBerate-HeFH Investigators. (2023). Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: the LIBerate-HeFH trial. European heart journal. DOI
  • Benachenhou S, Laroui A, Dionne O, Rojas D, Toupin A, Çaku A. (2023). Cholesterol alterations in fragile X syndrome, autism spectrum disorders and other neurodevelopmental disorders. International review of neurobiology. DOI
  • Lacroix A, Proteau-Lemieux M, Côté S, Near J, Hui SCN, Edden RAE, Lippé S, Çaku A, Corbin F, Lepage JF. (2022). Multimodal assessment of the GABA system in patients with fragile-X syndrome and neurofibromatosis of type 1. Neurobiology of disease. DOI
  • Abolghasemi A, Carullo MP, Aguilera EC, Laroui A, Plantefeve R, Rojas D, Benachenhou S, Ramírez MV, Proteau-Lemieux M, Lepage JF, Corbin F, Plourde M, Farez M, Cogram P, Çaku A. (2022). Alteration of Fatty Acid Profile in Fragile X Syndrome. International journal of molecular sciences. DOI
  • Laroui A, Galarneau L, Abolghasemi A, Benachenhou S, Plantefève R, Bouchouirab FZ, Lepage JF, Corbin F, Çaku A. (2022). Clinical significance of matrix metalloproteinase-9 in Fragile X Syndrome. Scientific reports. DOI
  • Toupin A, Benachenhou S, Abolghasemi A, Laroui A, Galarneau L, Fülöp T, Corbin F, Çaku A. (2022). Association of lipid rafts cholesterol with clinical profile in fragile X syndrome. Scientific reports. DOI
  • Champigny C, Morin-Parent F, Bellehumeur-Lefebvre L, Çaku A, Lepage JF, Corbin F. (2022). Combining Lovastatin and Minocycline for the Treatment of Fragile X Syndrome: Results From the LovaMiX Clinical Trial. Frontiers in psychiatry. DOI
  • Boutot ME, Whitcomb BW, Abdelouahab N, Baccarelli AA, Boivin A, Caku A, Gillet V, Martinez G, Pasquier JC, Zhu J, Takser L, St-Cyr L, Suvorov A. (2021). In Utero Exposure to Persistent Organic Pollutants and Childhood Lipid Levels. Metabolites. DOI
  • Proteau-Lemieux M, Lacroix A, Galarneau L, Corbin F, Lepage JF, Çaku A. (2021). The safety and efficacy of metformin in fragile X syndrome: An open-label study. Progress in neuro-psychopharmacology & biological psychiatry. DOI
  • Ben Djoudi Ouadda A, Gauthier MS, Susan-Resiga D, Girard E, Essalmani R, Black M, Marcinkiewicz J, Forget D, Hamelin J, Evagelidis A, Ly K, Day R, Galarneau L, Corbin F, Coulombe B, Çaku A, Tagliabracci VS, Seidah NG. (2019). Ser-Phosphorylation of PCSK9 (Proprotein Convertase Subtilisin-Kexin 9) by Fam20C (Family With Sequence Similarity 20, Member C) Kinase Enhances Its Ability to Degrade the LDLR (Low-Density Lipoprotein Receptor). Arteriosclerosis, thrombosis, and vascular biology. DOI
  • Benachenhou S, Etcheverry A, Galarneau L, Dubé J, Çaku A. (2019). Implication of hypocholesterolemia in autism spectrum disorder and its associated comorbidities: A retrospective case-control study. Autism research : official journal of the International Society for Autism Research. DOI
  • Paré G, Çaku A, McQueen M, Anand SS, Enas E, Clarke R, Boffa MB, Koschinsky M, Wang X, Yusuf S, INTERHEART Investigators. (2019). Lipoprotein(a) Levels and the Risk of Myocardial Infarction Among 7 Ethnic Groups. Circulation. DOI
  • Artuela Çaku, Nabil G. Seidah, Audrey Lortie, Nancy Gagné, Patrice Perron, Jean Dubé, Francois Corbin. (2017). New insights of altered lipid profile in Fragile X Syndrome. PLOS ONE. DOI
  • (2016). Lovastatin corrects ERK pathway hyperactivation in fragile X syndrome: potential of platelet’s signaling cascades as new outcome measures in clinical trials. Biomarkers.
  • (2014). Effect of lovastatin on behavior in children and adults with fragile X syndrome: An open-label study. American Journal of medical genetics.

Autres contributions

Cours enseignés ou supervisés à l'UdeS

  • BCH721 - Séminaire de biochimie médicale. (2024, 2026). (2CR).